U.S. markets close in 3 hours 31 minutes

Freeline Therapeutics Holdings plc (FRLN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.46+0.06 (+0.38%)
As of 10:16AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close16.40
Open16.42
Bid16.40 x 800
Ask16.60 x 1000
Day's Range16.40 - 16.58
52 Week Range15.25 - 21.69
Volume1,060
Avg. Volume203,885
Market Cap571.995M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Freeline to participate in Chardan’s 4th Annual Genetic Medicines Conference

      LONDON, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that Theresa Heggie, Chief Executive Officer, will present at the Chardan Virtual 4th Annual Global Healthcare Conference on October 6 at 4:45pm EDT. A live audio webcast of the presentation will be available on the investor relations section of Freeline’s website at https://www.freeline.life/investors-media/. An archived replay will be available on the Company’s website for a period of 30 days after the conference.About Freeline Freeline is a clinical-stage biotechnology company focused on AAV-based gene therapy targeting the liver. Its vision is to create better lives for people suffering from chronic, systemic diseases using the potential of gene therapy as a one-time treatment to provide a potential functional cure. Freeline is headquartered in the UK and has operations in Germany and the US.Forward-Looking Statements This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the Company’s strategies, financing plans, and clinical trial plans. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks and uncertainties, including the Company’s recurring losses from operations; the development of the Company’s product candidates, including statements regarding the timing of initiation, completion and the outcome of clinical studies or trials and related preparatory work; the Company’s ability to design and implement successful clinical trials for its product candidates; the potential for a pandemic, epidemic or outbreak of an infectious diseases in the U.S., U.K. or EU, including the COVID-19 pandemic, to disrupt the Company’s clinical trial pipeline; the Company’s failure to demonstrate the safety and efficacy of its product candidates; the fact that results obtained in earlier stage clinical testing may not be indicative of results in future clinical trials; the Company’s ability to enroll patients in clinical trials for its product candidates; the possibility that one or more of the Company’s product candidates may cause serious adverse, undesirable or unacceptable side effects or have other properties that could delay or prevent their regulatory approval or limit their commercial potential; the Company’s ability to obtain and maintain regulatory approval of its product candidates; the Company’s limited manufacturing experience which could result in delays in the development or commercialization of its product candidates; and the Company’s ability to identify or discover additional product candidates, or failure to capitalize on programmes or product candidates. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company  does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.For further information, please reference the Company’s reports and documents filed with the U.S. Securities and Exchange Commission. You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.Further information JW Communications Julia Wilson +44 (0) 7818 430877 juliawilsonuk@gmail.com

    • GlobeNewswire

      Freeline announces supply agreement for haemophilia B program

      LONDON, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical stage, fully-integrated, next generation, systemic, AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announces their supply agreement with Thermo Fisher Scientific Inc. (“Thermo Fisher”). This agreement secures dedicated production capacity and resources for Freeline from 2021 to 2027, inclusive. This will provide capacity for the planned Phase 2b/3 pivotal clinical trial and potential commercialisation of Freeline’s haemophilia B program, FLT180a, using the Company’s proprietary manufacturing platform and processes.Freeline has established the manufacturing process for FLT180a at Thermo Fisher’s Cambridge facility over the past two years, most recently initiating clinical supply production there for its planned Phase 2b/3 pivotal clinical trial of FLT180a.“I am delighted to announce this very significant extension of our partnership with Thermo Fisher,” said Jan Thirkettle, Chief Development Officer at Freeline. “The investment in, and commitment to, Thermo Fisher’s viral vector services operation gives us great confidence that they are the right partner to enable us to commercialise our haemophilia B therapy, if approved.”“As demand for new gene therapies continues to grow, we have made strategic investments to expand our viral vector commercial manufacturing capabilities so we can provide our customers with an uninterrupted pathway from development to commercialisation. A great example of this is the work we are doing with Freeline to support its program to develop a novel treatment for haemophilia B and we are pleased to partner with them on this,” said Chris Murphy, vice president and general manager for Thermo Fisher’s viral vector services business.About Freeline Freeline is a clinical-stage biotechnology company focused on AAV-based gene therapy targeting the liver. Its vision is to create better lives for people suffering from chronic, systemic diseases using the potential of gene therapy as a one-time treatment to provide a potential functional cure. Freeline is headquartered in the U.K. and has operations in Germany and the U.S.About Haemophilia Haemophilia is a genetic bleeding disorder where a protein made by the body to help make blood clot is either partly or completely missing. This protein is called a clotting factor. In haemophilia A, there is a deficiency of the clotting factor VIII (eight) protein and in haemophilia B, there is a deficiency of the clotting factor IX (nine) protein. Haemophilia mainly affects boys and men; however, women can be ‘carriers’ of the affected gene and may experience symptoms. Haemophilia A is the most common type of haemophilia affecting about one in every 5,000 males, while haemophilia B affects about one in every 30,000 males. Haemophilia is classified as mild, moderate or severe, depending on the level of clotting factor VIII or IX in the blood and is diagnosed through blood tests.About FLT180a The Freeline haemophilia B program, FLT180a, uses a synthetic AAVS3 capsid and a gain of function variant of human factor IX (FIX). The therapy is currently being studied in a Phase 1/2 trial with the goal of normalising FIX activity in patients with moderate and severe haemophilia.Forward-Looking Statements This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the Company’s strategies, financing plans, and clinical trial plans. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks and uncertainties, including the Company’s recurring losses from operations; the development of the Company’s product candidates, including statements regarding the timing of initiation, completion and the outcome of clinical studies or trials and related preparatory work; the Company’s ability to design and implement successful clinical trials for its product candidates; the potential for a pandemic, epidemic or outbreak of an infectious diseases in the U.S., U.K. or EU, including the COVID-19 pandemic, to disrupt the Company’s clinical trial pipeline; the Company’s failure to demonstrate the safety and efficacy of its product candidates; the fact that results obtained in earlier stage clinical testing may not be indicative of results in future clinical trials; the Company’s ability to enrol patients in clinical trials for its product candidates; the possibility that one or more of the Company’s product candidates may cause serious adverse, undesirable or unacceptable side effects or have other properties that could delay or prevent their regulatory approval or limit their commercial potential; the Company’s ability to obtain and maintain regulatory approval of its product candidates; the Company’s limited manufacturing experience which could result in delays in the development or commercialization of its product candidates; and the Company’s ability to identify or discover additional product candidates, or failure to capitalize on programs or product candidates. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please reference the Company’s reports and documents filed with the U.S. Securities and Exchange Commission. You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.Further information JW Communications Julia Wilson +44 (0) 7818 430877 juliawilsonuk@gmail.com

    • Morgan Stanley: 2 Strong Value Stocks to Buy Now
      TipRanks

      Morgan Stanley: 2 Strong Value Stocks to Buy Now

      Volatility is back on Wall Street. Following a meteoric rise, fears that valuations have grown too high have put pressure on stocks. With the upcoming presidential election, ongoing pandemic and flaring U.S.-China tensions only adding fuel to the fire, investors are trying to gauge where the market goes from here. Even though many economists believe the Fed’s low interest rate policy fueled the market’s historic five-month rally, Morgan Stanley's chief cross-asset strategist Andrew Sheets is singing a different tune.Sheets argues that the market’s charge forward wasn’t necessarily driven by the Fed’s actions. Rather, the run-up came as a result of better-than-expected economic data. “As much as the steady rise of markets seems disconnected from the conditions in the real economy, I'd argue that actually they're more closely related. And going forward, that is a double-edged sword,” he explained. "This improvement, rather than any new policy that central banks have been enacting, might be the real story of this summer's strength.”In other words, should the data slow, stocks might sink even if interest rates stay low. That said, if the trend continues to improve, stocks could continue climbing higher.Taking this outlook into consideration, we used TipRanks’ database to take a closer look at two names identified by Morgan Stanley as strong value stocks. The firm’s analysts noting that each could gain more than 40% in the year ahead.Freeline Therapeutics (FRLN)Using AAV technology, Freeline Therapeutics develops gene therapies to deliver safe and effective gene replacement to the liver to produce sustained therapeutic protein expression for diseases like hemophilia B and Fabry disease. Based on its cutting-edge pipeline, Morgan Stanley is pounding the table. Representing the firm, 5-star analyst Matthew Harrison points out that its “broad platform provides significant gene therapy opportunity, which can drive $1 billion-plus in unadjusted peak sales.” Highlighting its lead candidate, FLT180a, its gene therapy for hemophilia B (a disease that is characterized by decreased clotting and uncontrolled bleeding), the analyst believes it has major potential.The current standard of care for hemophilia B involves regular infusions of Factor IX (FIX) protein into the blood, but the FIX activity typically doesn’t remain stable. “FLT180a has the potential to deliver a single-dose cure for patients by achieving FIX levels in the ‘normal’ range of 50-150%. Although active clinical programs for hemophilia B include Spark/Pfizer and uniQure, they have been unable to achieve a mean expression level in the normal range. We thus believe that FLT180a has the potential to be a best-in-class product with $500 million-plus in peak sales potential,” Harrison commented.With the Phase 1/2 data already de-risking the asset, the implications go even further, in Harrison’s opinion. Along with the hemophilia B program, FRLN has another therapy, FLT190, targeting Fabry disease, a lysosomal storage disorder. While only one patient has been dosed, the analyst argues “the Freeline platform sets up this program for success.”Expounding on this, Harrison stated, “Given the data in hemophilia B, Freeline’s platform has high potency which can provide high protein expression levels at low doses, and Freeline’s prophylactic immune management regimen appears to prevent immune reactions, which could affect the durability of those high protein expression levels. Because FLT190 is using the same capsid and promoter and the same immune regimen as used for hemophilia B, we believe that, although still at an early stage, FLT190 is primed for success.”Adding to the good news, the company has early stage programs for hemophilia A, a multi-billion market, according to Morgan Stanley, and Gaucher disease, another lysosomal storage disorder. “While both programs are early, we believe the platform supports their potential,” Harrison mentioned.It should come as no surprise, then, that Harrison stayed with the bulls. To this end, he kept an Overweight (i.e. Buy) rating and $28 price target on the stock, implying 65% upside potential. (To watch Harrison’s track record, click here)What does the rest of the Street have to say? Only Buy ratings, 4 in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. In addition, the $28.75 average price target suggests 69% upside potential. (See FRLN stock analysis on TipRanks)Cloudera Inc. (CLDR)Switching gears now, we come across Cloudera, which delivers an enterprise data cloud for any data, anywhere, from the Edge to AI. Even with ARR ramping up, Morgan Stanley believes this tech company is undervalued.Firm analyst Sanjit Singh points to CLDR’s Q2 performance as reaffirming his confidence. “Q2 results highlight what has been true now for several quarters – CLDR is now a much more stable business.”Digging into the details of the print, ARR accelerated to 12% year-over-year, beating the consensus estimate. Subscription revenue growth came in at 17%, also besting the Street’s 14.5% call. The outperformance continued when it came to operating margins and cash flow, which landed at 13.9% and $32 million, respectively. “Resilience within the customer base underscored by improvement in churn rates combined with sharp operational execution helped management raise its FY21 subscription revenue outlook to $755-$765 million (13-15%) from $745-$755 million prior,” Singh noted.Following the strong print, there is one question on investors’ minds. As both the CDP Public Cloud and CDP Private Cloud have now been officially launched, will the CDP platform become a key revenue driver?Addressing this question, Singh commented, “The early signs are encouraging with customer count and bookings doubling in the quarter. Management expects revenue traction in FY22 and we are cautiously optimistic that CDP can enable modest improvement in growth particularly as the spending environment recovers.”Some investors were taken aback by CLDR’s Q3 subscription revenue guidance, which implies a minor quarter-over-quarter decline, but Singh offers an explanation. “This reflects the impact of becoming a pure open source model which results in less up-front revenue recognition vs. Last year when Cloudera was operating a part proprietary/open source model,” he stated.Summing it all up, Singh said, “Recent results highlight management's ability to meet investor expectations while delivering on key product milestones, most notably CDP, which better positions the company in the data management market. We see the launch of CDP sustaining growth by improving retention rates and securing new customers as the spending environment recovers. Furthermore, a growing focus on larger enterprises should provide leverage going forward given their more attractive unit economics. With low expectations, achievable ARR estimates and a new product cycle, we see shares attractively valued.”All of the positives prompted Singh to leave his bullish call and $16 price target unchanged. This target conveys Singh’s confidence in CLDR’s ability to climb 46% higher in the next year. (To watch Singh’s track record, click here)Looking at the consensus breakdown, 4 Buys, 6 Holds and 1 Sell have been published in the last three months. Therefore, CLDR gets a Moderate Buy consensus rating. Based on the $14.50 average price target, shares could rise 32% in the next year. (See CLDR stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.